Skip to main content
54°
Clear
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Amgen
(NQ:
AMGN
)
330.64
+0.13 (+0.04%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Amgen
< Previous
1
2
...
8
9
10
11
12
13
14
15
16
...
40
41
Next >
Looking At Amgen's Recent Unusual Options Activity
October 23, 2023
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
October 18, 2023
Via
Benzinga
Amgen Unusual Options Activity For October 17
October 17, 2023
Via
Benzinga
$100 Invested In Amgen 15 Years Ago Would Be Worth This Much Today
October 16, 2023
Via
Benzinga
Johnson & Johnson Stock: Is Now the Time to Sell?
October 14, 2023
Conservative investors buy Johnson & Johnson for the dividend, but that payout is less safe after its Kenvue spinoff
Via
InvestorPlace
In-Depth Analysis: Amgen Versus Competitors In Biotechnology Industry
October 13, 2023
Via
Benzinga
Is This Dividend Stock a Screaming Buy After Its Latest Acquisition?
October 13, 2023
The biotech is ending the year with a bang.
Via
The Motley Fool
Is Amgen Stock a Buy Now?
October 13, 2023
The company recently closed its acquisition of Horizon Therapeutics.
Via
The Motley Fool
Check Out What Whales Are Doing With AMGN
October 12, 2023
Via
Benzinga
Amgen Stock Surges To 10-Month High, Up 4% On An Unexpected Upgrade
October 11, 2023
The company has growing pipeline optionality, according to the upgrade report.
Via
Investor's Business Daily
10 Health Care Stocks Whale Activity In Today's Session
October 11, 2023
Via
Benzinga
Expert Ratings for Amgen
October 11, 2023
Via
Benzinga
Should You Still Buy the Nasdaq's Best-Performing September Stocks?
October 10, 2023
Tech stocks sold off last month, but these three were gainers.
Via
The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
October 09, 2023
Via
Benzinga
$100 Invested In This Stock 15 Years Ago Would Be Worth $500 Today
October 09, 2023
Via
Benzinga
Check Out What Whales Are Doing With AMGN
September 29, 2023
Via
Benzinga
2 Magnificent Dividend Stocks to Buy Hand Over Fist in October
October 09, 2023
These two healthcare stocks are reliable passive income vehicles.
Via
The Motley Fool
Mirati Therapeutics Snags $5.8 Billion Takeover Deal, But Shares Fall On Lowball Bid
October 09, 2023
Bristol Myers Squibb hopes to buy Mirati Therapeutics for up to $5.8 billion.
Via
Investor's Business Daily
Amgen's Adcomm Meeting Paves Way To Launch Boost For Mirati Therapeutics' Lung Cancer Drug: Analysts
October 06, 2023
According to a report on Thursday, French pharma company Sanofi SA (NASDAQ: SNY) is reportedly exploring a potential acquisition of cancer drugmaker Mirati Therapeutics Inc (NASDAQ: MRTX).
Via
Benzinga
FDA Adcomm Gives Thumbs Down To Amgen's Lumakras For Advanced Form Of Lung Cancer
October 06, 2023
FDA advisers concluded that the data from a late-stage trial lacked the requisite reliability to endorse the traditional approval of Amgen Inc's (NASDAQ: AMGN) Lumakras for patients afflicted with an...
Via
Benzinga
Exposures
Product Safety
Biotech Sector: On The Verge Of Triumph Or Turmoil?
October 06, 2023
In this article, we delve into the Biotech Sector, exploring its promises, potential pitfalls, and the questions that arise.
Via
Talk Markets
Should You Still Buy the Dow Jones' Best-Performing September Stocks?
October 04, 2023
A handful of blue-chip tickers defied the bigger bearish tide last month, but that doesn't necessarily make these stocks a buy.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
Is Amgen's Lung Cancer Drug Lumakras Up to the Mark? FDA Briefing Raises Concerns
October 03, 2023
The FDA released briefing documents ahead of Oncologic Drugs Advisory Committee meeting scheduled for October 5 to review Amgen Inc's (NASDAQ:
Via
Benzinga
Exposures
Product Safety
Drugmakers Agree To Participate For Medicare Drug Price Negotiation With Biden Administration
October 03, 2023
All ten manufacturers of the first drugs selected for Medicare price negotiations will be participating, the White House said, even though many of them are suing the administration
Via
Benzinga
AskSlim Market Week - Friday, Sep. 29
September 29, 2023
Technical and cycle analysis, and market commentary.
Via
Talk Markets
3 Biotech Stocks to Watch Ahead of Potential Obesity Drug Approvals
September 28, 2023
The demand for biotech stocks is intense and is likely to only greatly increase going forward, especially in the United States.
Via
InvestorPlace
September's Shakeout: S&P 500, Nasdaq 100 See Just 13% Of Stocks Above 50-Day Average
September 27, 2023
The September market downturn is spreading like wildfire across various sectors, with only a handful of stocks managing to maintain the positive trend seen in recent months.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
FDA Strikes Off Coherus BioSciences' New Injector Biosimilar Treatment For Cancer Patients
September 25, 2023
The FDA issued a Complete Response Letter regarding the Biologics License Application supplement for Udenyca Onbody, Coherus BioSciences Inc's (NASDAQ: CHRS) on-body injector (OBI) presentation of...
Via
Benzinga
Exposures
Product Safety
AI To Revolutionize Clinical Trials And Diagnostics
September 22, 2023
With the help of technology, the pharmaceutical industry is gaining new insights that are fueling the development of next generation of drugs while also speeding up clinical trials and improving...
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
From Years to Months: How AI is Shaping the Landscape of Clinical Trials
September 22, 2023
Pharmaceutical companies are harnessing artificial intelligence (AI) to speed up the traditionally arduous process of clinical trials, potentially saving both time and significant sums of money. These...
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
< Previous
1
2
...
8
9
10
11
12
13
14
15
16
...
40
41
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.